Long Term: West Pharmaceutical Services
Explore this signal
Long Term at a glance
Short reader summary
More complex injectable medicines could need higher-specification vial stoppers and delivery components, allowing a qualified supplier to capture repeat demand.
Exact asset or item
West Pharmaceutical Services
Asset type
Listed investment
Reference price
416.42
Currency code
USD
Price observed at
2026-11-13T16:00:00-05:00
What this number represents
Tracking price
What remains unproven
Historical tracking close, not a purchase or current executable entry. Product mix, customer concentration, fair value and future share appreciation remain unproven.
Exact asset or item
Exact asset or item
West Pharmaceutical Services
Asset type
Listed investment
Ticker
WST
Exchange
NYSE
How to identify this exact asset
NYSE: WST common listed equity; United States / USD. Source dossier: 15 November 2026, 16:55 SGT. Main time horizon: 2 years. CONDITIONAL OPPORTUNITY.
Price and what it means
Entry or reference price
416.42
Currency code
USD
Price observed at
2026-11-13T16:00:00-05:00
What this number represents
Tracking price
Price evidence status
Verified
Price source
8. WST historical closing price
Publisher: Stock Analysis
Original language: English
Reading access: partial
Underlying origin: WST-S8
published date precision: day
retrieved date precision: day
Source publication date 2026-11-13
Source retrieval date 2026-11-16
Matching price source ID
WST-S8
Purchase, sale and realised profit
Permanent original reference: USD 416.42 / Friday 13 November 2026, 16:00 EST / Stock Analysis historical closing-price page (URL as final source). This stays frozen for future corrections. Latest checked price: same 13 November historical close; no newer US session by this Sunday cutoff. Price change since original entry: 0.00 USD at this same reference observation only, NOT a trading gain; no new independent current executable price. Estimated result after costs: not assessable (zero executed shares; brokerage, spreads, FX and taxes are unknown). Actually sold: NO (no purchase was made). Forecast status: NOT YET DUE / UNRESOLVED. Next review: 15 May 2027; earlier trigger on next published company quarterly release. Preserve this baseline even if subsequent results contradict the thesis.
The developments we connected
Separate development
What changed
Q1 component growth
Date of the development
Evidence status
Observed
What the evidence shows
Q1 revenue about USD 844.9 million with strong high-value product growth.
Source IDs
- WST-S3
What changed
Q2 component demand
Date of the development
Evidence status
Observed
What the evidence shows
Q2 sales about USD 872.3 million, up about 13.8% as reported.
Source IDs
- WST-S2
What changed
Q3 component growth and division weakness
Date of the development
Evidence status
Observed
What the evidence shows
Q3 sales about USD 874.5 million, up 8.7% reported; high-value components organic sales up 20.3%, while West Vantage declined 6.6% organically.
Source IDs
- WST-S1
Emerging insight
REPORT A (23 April: HVP sales accelerate) -> REPORT B (23 July: sustained products mix change) -> REPORT C (29 October: HVP demand still strong even as a different division weakens). Regulatory background from EU sterilisation rules adds a quality hurdle. Hidden link: after a sterile component is validated for a drug, switching providers can require costly re-qualification, which could aid repeat orders. This is a hypothesis about customer behaviour, not disclosed customer-specific contract pricing.
How this exact asset could benefit
Beneficiary: West through elastomer components, containment and device manufacturing. Proven: company-reported growth in higher-value components and cash-generation history. Not proven: all growth comes from GLP-1 drugs, regulation caused 2026 sales, market share increased, or the premium valuation will persist. Drug approval and a stopper sale are separate outcomes.
Who could benefit
Who
West Pharmaceutical Services
How they could benefit
Beneficiary: West through elastomer components, containment and device manufacturing. Proven: company-reported growth in higher-value components and cash-generation history. Not proven: all growth comes from GLP-1 drugs, regulation caused 2026 sales, market share increased, or the premium valuation will persist. Drug approval and a stopper sale are separate outcomes.
Evidence status
Still unproven
What we observed
23 April 2026, Pennsylvania: West reported Q1 revenue about USD 844.9 million with strong high-value product (HVP) growth. 23 July: Q2 sales about USD 872.3 million, up about 13.8% as reported. 29 October: Q3 sales about USD 874.5 million, up 8.7% reported, and high-value components organic sales up 20.3%, but the West Vantage division was down 6.6% on an organic basis. The European Commission maintains Annex 1 sterile-manufacturing guidance; most of the update took effect before 2026 and is not a new October 2026 regulation.
What remains unproven
Beneficiary: West through elastomer components, containment and device manufacturing. Proven: company-reported growth in higher-value components and cash-generation history. Not proven: all growth comes from GLP-1 drugs, regulation caused 2026 sales, market share increased, or the premium valuation will persist. Drug approval and a stopper sale are separate outcomes.
What to check before acting
Entry conditions
Read HVP organic-growth tables and quarterly cash flow; distinguish total revenue from division mix. Check customers concentration and regulatory disclosures. Do not assume one medicine can be linked to one WST component without product-level proof.
Possible upside
Upside: re-qualification friction preserves recurring high-margin component sales.
Possible downside
Downside: demand returns to lower-value parts and a high stock multiple contracts.
Price or return range method
Downside: demand returns to lower-value parts and a high stock multiple contracts. Base: premium products continue to take share of West revenue, with uneven segment growth. Upside: re-qualification friction preserves recurring high-margin component sales. Numerical future-price range: not estimated given uncertain product mix and drug/customer concentration. Publishing verification, 16 November 2026: historical close divided by FY2026 adjusted EPS guidance yields approximately 43.93–44.39 times, not a fair-value estimate. Numerical price targets are not supported by a verified terminal multiple or product/customer mix forecast.
Costs and fees
Spreads, broker/FX costs, exchange taxes where applicable and price gaps matter; no universal tax assumption.
How hard it may be to sell
NYSE trading is generally possible, but spreads, broker/FX costs, exchange taxes where applicable and price gaps matter; no universal tax assumption.
Key risks
Large drug companies may diversify suppliers or reduce orders after inventory stocking; process faults or recalls can be costly. Alternate explanation: a short-lived injectable-drug capacity boom. Disproof: HVP component organic sales growth under 5% for two successive quarters plus negative free cash flow across a subsequent year. NYSE trading is generally possible, but spreads, broker/FX costs, exchange taxes where applicable and price gaps matter; no universal tax assumption.
What an ordinary reader can do next
Read HVP organic-growth tables and quarterly cash flow; distinguish total revenue from division mix. Check customers concentration and regulatory disclosures. Do not assume one medicine can be linked to one WST component without product-level proof. Next quarterly West release date not confirmed. Compare HVP component sales with West Vantage and inspect whether Q3 inventory/seasonality reverses.
Original forecast record
Original forecast in full
Long Term: West Pharmaceutical Services
Category: Shares
Exact asset: NYSE: WST common listed equity
Country and currency: United States / USD
Published: 15 November 2026, 16:55 SGT
Information cutoff: 15 November 2026, 16:55 SGT
Main time horizon: 2 years
Current position: CONDITIONAL OPPORTUNITY
Publication clarification: 16 November 2026 (SGT). The 'Published' time in the source metadata above is the source dossier's issue time, not this website article's first-publication time. The live page records actual first publication separately.
The opportunity in one sentence
More complex injectable medicines could need higher-specification vial stoppers and delivery components, allowing a qualified supplier to capture repeat demand.
Entry price and date
Reference entry price: USD 416.42 per share; price observed Friday 13 November 2026 at 16:00 EST (Saturday 14 November 05:00 SGT), Stock Analysis history (underlying reported S&P Global Market Intelligence market data). Type of price: historical closing market quote, not broker order quote. Availability: listed common stock generally broker-accessible where legally allowed. Entry note: TRACKING PRICE ONLY, NOT AN ACTUAL PURCHASE.
What changed?
23 April 2026, Pennsylvania: West reported Q1 revenue about USD 844.9 million with strong high-value product (HVP) growth. 23 July: Q2 sales about USD 872.3 million, up about 13.8% as reported. 29 October: Q3 sales about USD 874.5 million, up 8.7% reported, and high-value components organic sales up 20.3%, but the West Vantage division was down 6.6% on an organic basis. The European Commission maintains Annex 1 sterile-manufacturing guidance; most of the update took effect before 2026 and is not a new October 2026 regulation.
View chart values
| Quarter | Revenue (US$ million) |
|---|---|
| Q1 2026 | 844.9 |
| Q2 2026 | 872.3 |
| Q3 2026 | 874.5 |
- 1. Third-quarter 2026 results · 2026-10-29
- 2. Second-quarter 2026 results · 2026-07-23
- 3. First-quarter 2026 results · 2026-04-23
The connection most people may miss
REPORT A (23 April: HVP sales accelerate) -> REPORT B (23 July: sustained products mix change) -> REPORT C (29 October: HVP demand still strong even as a different division weakens). Regulatory background from EU sterilisation rules adds a quality hurdle. Hidden link: after a sterile component is validated for a drug, switching providers can require costly re-qualification, which could aid repeat orders. This is a hypothesis about customer behaviour, not disclosed customer-specific contract pricing.
- Validated sterile componentQualified for a particular drug or process
- Possible switching costChanging supplier may require requalification
- Potential repeat ordersOnly if customers retain the supplier
- Possible durable cashOnly after costs, investment and cash collection
- European Commission sterile GMP background · 2022 Annex 1 revision; implementation 2023–2024
- West Q3 2026 results · 29 October 2026
How this could make money
Beneficiary: West through elastomer components, containment and device manufacturing. Proven: company-reported growth in higher-value components and cash-generation history. Not proven: all growth comes from GLP-1 drugs, regulation caused 2026 sales, market share increased, or the premium valuation will persist. Drug approval and a stopper sale are separate outcomes.
Why the entry price matters
USD 416.42 is a historical quote. Valuation needs sustainable free cash flow, capacity investments, organic HVP revenue excluding one-off stocking, R&D and capital needs. A high multiple leaves a long way to fall if premium-component growth normalises; no defendable entry discount is established.
Time-horizon forecast
| Horizon | Review date | What we expect or need to see | What would challenge it |
|---|---|---|---|
| 6 months | 15 May 2027 | HVP growth and cash checks from two newer quarters | HVP slows or operating cash weakens |
| 1 year | 15 Nov 2027 | Full-year quality-component organic growth and FCF | Division weakness outweighs premium demand |
| 2 years | 15 Nov 2028 | Repeat high-value mix growth, robust margins | Inventory correction rather than durable demand |
| 3 years | 15 Nov 2029 | Capacity earnings after maintenance capex | Customer losses or product failure |
| 4 years | 15 Nov 2030 | Quality moat reflected in sustained cash per share | Price concessions and commoditisation |
| 5 years | 15 Nov 2031 | Long-run earnings track drug demand without boom pricing | Not enough evidence yet |
- OTR West Pharmaceutical source dossier · 15 November 2026, 16:55 SGT
Possible price outcomes
Downside: demand returns to lower-value parts and a high stock multiple contracts. Base: premium products continue to take share of West revenue, with uneven segment growth. Upside: re-qualification friction preserves recurring high-margin component sales. Numerical future-price range: not estimated given uncertain product mix and drug/customer concentration.
What could go wrong?
Large drug companies may diversify suppliers or reduce orders after inventory stocking; process faults or recalls can be costly. Alternate explanation: a short-lived injectable-drug capacity boom. Disproof: HVP component organic sales growth under 5% for two successive quarters plus negative free cash flow across a subsequent year. NYSE trading is generally possible, but spreads, broker/FX costs, exchange taxes where applicable and price gaps matter; no universal tax assumption.
What an ordinary person can do
Read HVP organic-growth tables and quarterly cash flow; distinguish total revenue from division mix. Check customers concentration and regulatory disclosures. Do not assume one medicine can be linked to one WST component without product-level proof.
What happens next?
Next quarterly West release date not confirmed. Compare HVP component sales with West Vantage and inspect whether Q3 inventory/seasonality reverses.
OTR tracking record
Permanent original reference: USD 416.42 / Friday 13 November 2026, 16:00 EST / Stock Analysis historical closing-price page (URL as final source). This stays frozen for future corrections. Latest checked price: same 13 November historical close; no newer US session by this Sunday cutoff. Price change since original entry: 0.00 USD at this same reference observation only, NOT a trading gain; no new independent current executable price. Estimated result after costs: not assessable (zero executed shares; brokerage, spreads, FX and taxes are unknown). Actually sold: NO (no purchase was made). Forecast status: NOT YET DUE / UNRESOLVED. Next review: 15 May 2027; earlier trigger on next published company quarterly release. Preserve this baseline even if subsequent results contradict the thesis.
Publishing verification
16 November 2026 (SGT). All eight original source links reopened successfully; the source dossier's earlier Q2 access limitation was not reproduced. Annex 1 generally applied from 25 August 2023, with point 8.123 applying from 25 August 2024. USD 416.42 remains the 13 November regular-session historical close, not an executable entry price. Entry price unavailable: no current executable quote was obtained. The separately observed USD 414.57 after-hours quote, dated 13 November 2026 at 19:53 EST (14 November 08:53 SGT), is not a replacement for the frozen reference. Issuer FY2026 adjusted EPS guidance of USD 9.38–9.48 implies a historical-price/forward-guidance ratio of approximately 43.93–44.39 times (416.42 divided by EPS). This is not fair value or a return forecast. No supported terminal multiple, product-mix or customer-concentration forecast establishes numerical multi-year price targets.
Original forecast date and time
2026-11-15T16:55:00+08:00
Forecasts and review dates
6 months
Review date
2027-05-15
Original forecast
HVP growth and cash checks from two newer quarters
What to measure
HVP growth and cash checks from two newer quarters
What must happen
HVP growth and cash checks from two newer quarters
What would challenge the forecast
HVP slows or operating cash weakens
Current outcome
Not yet due
1 year
Review date
2027-11-15
Original forecast
Full-year quality-component organic growth and FCF
What to measure
Full-year quality-component organic growth and FCF
What must happen
Full-year quality-component organic growth and FCF
What would challenge the forecast
Division weakness outweighs premium demand
Current outcome
Not yet due
2 years
Review date
2028-11-15
Original forecast
Repeat high-value mix growth, robust margins
What to measure
Repeat high-value mix growth, robust margins
What must happen
Repeat high-value mix growth, robust margins
What would challenge the forecast
Inventory correction rather than durable demand
Current outcome
Not yet due
3 years
Review date
2029-11-15
Original forecast
Capacity earnings after maintenance capex
What to measure
Capacity earnings after maintenance capex
What must happen
Capacity earnings after maintenance capex
What would challenge the forecast
Customer losses or product failure
Current outcome
Not yet due
4 years
Review date
2030-11-15
Original forecast
Quality moat reflected in sustained cash per share
What to measure
Quality moat reflected in sustained cash per share
What must happen
Quality moat reflected in sustained cash per share
What would challenge the forecast
Price concessions and commoditisation
Current outcome
Not yet due
5 years
Review date
2031-11-15
Original forecast
Long-run earnings track drug demand without boom pricing
What to measure
Long-run earnings track drug demand without boom pricing
What must happen
Long-run earnings track drug demand without boom pricing
What would challenge the forecast
Not enough evidence yet
Current outcome
Not yet due
Sources
Dated source
Source ID
WST-S1
Source link and publication date
Publisher: West Pharmaceutical Services
Original language: English
Reading access: partial
Underlying origin: WST-S1
published date precision: day
retrieved date precision: day
Source publication date 2026-10-29
Source retrieval date 2026-11-16
What this source supports
Supports: HVP growth and West Vantage counter-evidence. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.
Source ID
WST-S2
Source link and publication date
2. Second-quarter 2026 results
Publisher: West Pharmaceutical Services
Original language: English
Reading access: partial
Underlying origin: WST-S2
published date precision: day
retrieved date precision: day
Source publication date 2026-07-23
Source retrieval date 2026-11-16
What this source supports
Supports: Mid-year component demand. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: 403 on direct open; indexed excerpt checked.
Source ID
WST-S3
Source link and publication date
Publisher: West Pharmaceutical Services
Original language: English
Reading access: partial
Underlying origin: WST-S3
published date precision: day
retrieved date precision: day
Source publication date 2026-04-23
Source retrieval date 2026-11-16
What this source supports
Supports: Earlier HVP evidence. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.
Source ID
WST-S4
Source link and publication date
4. Fourth-quarter/full-year 2025 results
Publisher: West Pharmaceutical Services
Original language: English
Reading access: partial
Underlying origin: WST-S4
published date precision: day
retrieved date precision: day
Source publication date 2026-02-12
Source retrieval date 2026-11-16
What this source supports
Supports: Historical baseline and reporting methods. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.
Source ID
WST-S5
Source link and publication date
Publisher: West Pharmaceutical Services
Original language: English
Reading access: partial
Underlying origin: WST-S5
published date precision: day
retrieved date precision: day
Source publication date 2025-10-23
Source retrieval date 2026-11-16
What this source supports
Supports: Like-for-like previous-year comparison. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.
Source ID
WST-S6
Source link and publication date
6. EudraLex Volume 4 Annex 1 and sterile GMP
Publisher: European Commission
Original language: English
Reading access: partial
Underlying origin: WST-S6
published date precision: day
retrieved date precision: day
Source publication date 2022-08-25
Source retrieval date 2026-11-16
What this source supports
Supports: Existing quality regime, not newly enacted 2026. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.
Source ID
WST-S7
Source link and publication date
7. Q3 2026 earnings transcript
Publisher: Stock Analysis
Original language: English
Reading access: partial
Underlying origin: WST-S7
published date precision: day
retrieved date precision: day
Source publication date 2026-10-29
Source retrieval date 2026-11-16
What this source supports
Supports: Question/answer context and counter-evidence. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Indexed secondary transcript; verify against issuer webcast.
Source ID
WST-S8
Source link and publication date
8. WST historical closing price
Publisher: Stock Analysis
Original language: English
Reading access: partial
Underlying origin: WST-S8
published date precision: day
retrieved date precision: day
Source publication date 2026-11-13
Source retrieval date 2026-11-16
What this source supports
Supports: USD 416.42 close for frozen tracking. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.
Source limits
Original source register
Each entry specifies the source and what it can establish. Retrieval checkpoint is a single edition-level check, not a claim to individual upstream HTTP completion clocks. Links are genuine direct URLs but some access remains partial.
1. Third-quarter 2026 results | West Pharmaceutical Services | source date: 29 Oct 2026 | US / English
Supports: HVP growth and West Vantage counter-evidence. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.
2. Second-quarter 2026 results | West Pharmaceutical Services | source date: 23 Jul 2026 | US / English
Supports: Mid-year component demand. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: 403 on direct open; indexed excerpt checked.
3. First-quarter 2026 results | West Pharmaceutical Services | source date: 23 Apr 2026 | US / English
Supports: Earlier HVP evidence. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.
4. Fourth-quarter/full-year 2025 results | West Pharmaceutical Services | source date: 12 Feb 2026 | US / English
Supports: Historical baseline and reporting methods. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.
5. Third-quarter 2025 results | West Pharmaceutical Services | source date: 23 Oct 2025 | US / English
Supports: Like-for-like previous-year comparison. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.
6. EudraLex Volume 4 Annex 1 and sterile GMP | European Commission | source date: 2022 Annex 1 revision; implementation largely 25 Aug 2023, some provisions 2024 | EU / English
https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
Supports: Existing quality regime, not newly enacted 2026. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.
7. Q3 2026 earnings transcript | Stock Analysis | source date: Q3 2026, exact publication time not verified | US / English
https://stockanalysis.com/stocks/wst/transcripts/713957-q3-2026/
Supports: Question/answer context and counter-evidence. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Indexed secondary transcript; verify against issuer webcast.
8. WST historical closing price | Stock Analysis / S&P Global Market Intelligence | source date: 13 Nov 2026 | US / English
https://stockanalysis.com/stocks/wst/history/
Supports: USD 416.42 close for frozen tracking. Reviewed: 15 November 2026, 16:55 SGT (edition-level source review checkpoint; HTTP completion clocks unavailable). Access: Opened/checked through web; date of HTTP retrieval not independently provided.